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ABSTRACT 
 
Cancer is a disease that affects major part of the human population. Though, centuries have 
been spent upon cancer research many aspects of cancer cell are still undiscovered and thus 
there has been no effective drug designed that can actually cure cancer. Pyruvate Kinase M2 
tumor isoform has been used as a target since 1972, when it was first time discovered. Though, 
after a series of scientific research, no promising results have been found. There is a need of 
much intensive research upon this protein as, this protein plays a major role in energy 
generation as well as, generation of macromolecules which are required for cancer cell 
proliferation. 
In this project, various small molecule inhibitors were docked with tumor-PKM2, to check 
whether they can be used to inhibit the particular protein. Different binding/ active sites of the 
target protein were used to dock with inhibitors using Auto Dock Vina software. The results 
showed that set of molecules Kaempferol, L-Phosphophenol and Soc3 showed high affinity 
towards the protein. Also, some of their analogues gave good results. Kaempferol showed high 
binding efficiency of -7.8Kcal/mol. Quercetin was a ligand that showed highest efficiency of 
about -8.1 Kcal/mol at all binding sites. The above molecules that showed high binding 
efficiency can be used as inhibitors of tumor-PKM2, when attached to cancer specific markers.. 
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1.1 Introduction: 
 
Cancer is a disease that is basically defined as unregulated cell growth. Cells divide and grow 
in an abnormal way to form tumors. Tumors can be benign or malignant, by their capacity to 
invade lymphatic and circulatory system, and reach other parts of the body. Cancer cells are 
proposed to have six characteristic features which include - self-sufficiency in growth 
signalling, insensitivity to death signals, evasion of cell apoptosis, exceptional replication 
potential, induced angiogenesis and tissue invasion or metastasis. 
The causes of cancer may depend upon various factors such as environmental factors or genetic 
factors. Other common factors might be chemicals, diet, infection, radiation, hormones or 
genetic disorders.  
All these factors lead to genetic variations that lead to alterations in functioning of genes in 
proper desired manner. The genes that have role in cell growth, differentiation, and cell death 
are altered that lead to loss of function or gain of unwanted functions and hence abnormal cell 
signalling pathways. 
 
1.1.1 Cancer cell metabolism: 
For cell division three basic requirements are - rapid generation of ATP, increased synthesis of 
nucleic acids and amino acids, and maintenance of balanced redox status. In case of cancer 
cells, there is an alteration in metabolic synthesis of all macromolecules. These occur due to 
the mutations, translocations, deletions and amplifications of genetic material of cells. The 
major alterations in cancer cell metabolism are centred among - PI3K/ATK signalling pathway, 
JAK/STAT pathway, NOTCH signalling, MAP kinase / ERK pathway, NF/KB pathway and 
Glycolysis. 
 
1.1.2 Warburg Effect: 
Along with the energy required for cell survival, cancer cells require high amount of energy 
for cell proliferation. Reprogramming of metabolic pathways in cancer cells is an essential step 
for continuous growth and division. Warburg effect is the hallmark of most cancer cells where 
aerobic glycolysis occurs in presence of oxygen. There is high glucose uptake in cancer cells 
and high lactic acid production. This was derived from the increased glycolytic flux which 
served as compensatory mechanism of energy source for tumor cells. In cancer cells there is 
an altered glycolysis which is the major source of energy here. In normal cells, the end product 
of glycolysis is pyruvate, which is transferred into the mitochondria for further functioning. 
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But, in case of cancer cells the pyruvate is converted into lactate which remains in the 
cytoplasm of the cell. This is due to the functioning of tumor-PKM2 (isomer of pyruvate kinase 
M2 form) which is highly expressed in proliferating cells. 
 
1.1.3 Tumor-PKM2 : 
Tumor-PKM2 is a dimeric form of pyruvate kinase isoenzyme. This iso-enzyme has been 
found to be elevated in several types of cancer such as gastro-intestinal cancer, colon cancer, 
breast cancer etc. Pyruvate Kinase catalyses the last step of glycolysis, which is the step of net 
energy generation. This dimeric form of M2PK in cancer cells is the result of interactions 
between M2PK and various onco-proteins.  
 
Figure 1. Role of tumor-PKM2 in glycolysis. 
Thus, tumor-PKM2 plays a crucial role in energy generation pathway as well as in transfer of 
glycolytic metabolites towards synthesis of macromolecules required for growth and 
proliferation of cell. Hence, this protein can be targeted for inhibition for cancer therapy with 
use of proper cancer cell specific marker. 
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  1.2 Objective:  
 
 To identify various cancer cell specific pathways, or alterations in the pathways to 
select a specific target protein. 
 To find inhibitors for the specific target protein i.e. tumor-pyruvate kinase M2 from 
past literatures. 
 To carry out molecular docking of inhibitors with tumor-PKM2 and assessing their 
binding affinity. 
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2.1 Cancer Cell Metabolism: 
The mutations that lead to cancer affect a dozen of main signalling pathways and processes 
that lead to malfunctioning of cellular responses and lead to tumorigenesis (Parsons et al., 
2008). To support the growth and metabolism of cancer cells these metabolic pathways 
converge together. Thereby, to keep continuous flow of energy in the form of ATP, and 
generation of nucleic acids and amino acids, the molecular mechanisms alter and converge with 
the cellular metabolisms (Carins et al., 2011). There is somewhat a similarity of metabolism in 
case of highly proliferating normal cells and cancer cells. Macromolecules like carbohydrates, 
proteins, nucleic acids and lipids are in great demand and hence there is the need for alteration 
in the cellular pathways. Due to the high lactic acid concentrations in tumor cells, one of the 
major pathways to concentrate upon is the glycolytic pathway in cancer cells which is the major 
energy generation pathway (Gatenby and Gillies, 2007). Due to the high dependency of cancer 
cells upon anaerobic metabolism, which is a significant source of energy, inhibition of 
glycolytic pathway seems promising which might exploit high consumption of glucose 
(Gatenby and Gillies, 2007). Under hypoxic conditions, glucose or energy deprivation from 
glycolytic source may lead to cell death (Gatenby and Gillies, 2007).  
 
2.1.1 Glycolytic Pathway in Cancer Cells (Warburg Effect): 
Most of the energy generation i.e. ATP synthesis in cancer cells is through glycolysis under 
aerobic conditions. There is shift in ATP production towards glycolysis as the activity of 
mitochondria slows down (Gogvadze et al., 2010). Apart from energy generation the major 
importance of glycolysis is to provide high concentrations of glycolytic intermediates so as to 
promote synthesis of macromolecules in highly proliferating cells (Kwon and Heiden, 2011). 
In case of cancer cells, for growth and proliferation there is a high requirement of nutrients for 
their conversion into biosynthetic building blocks. For this purpose there is a need for high 
concentration of glycolytic intermediates and alterations of the reactions and pathways 
necessary for their transformation into macromolecules required for generation of new cells 
(Kwon and Heiden, 2011). For this purpose to satisfy the cell’s need for energy and metabolites 
there is a high consumption of glucose by tumor cells and hence high amount of lactic acid 
concentration (http://www.cellsignal.com/contents/science-pathway-research-cellular-
metabolism/warburg-effect-signaling-pathway/pathways-warburg).  
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Figure 2. Warburg Effect in Cancer cells (http://www.cellsignal.com/contents/science-
pathway-research-cellular-metabolism/warburg-effect-signaling-pathway/pathways-
warburg). 
It was observed by Warburg that in normal cells in presence of oxygen most of the energy 
(ATP) was generated in mitochondrial respiration. But, it was then noted that over 50% of 
cell’s energy was generated in cytosol in case of cancer cells. Thus, to meet the energy 
demands, cancer cells must adopt to increase glucose intake to meet energy demands (Dakubo, 
2010). 
 
2.1.2. Pyruvate Kinase M2 (tumor isoform): 
 
Pyruvate kinase M2 is an isomer of pyruvate kinase. There are four such isomers, which are 
expressed depending upon requirement for metabolic function of tissues (Corcoran et al., 
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1976). Primary function of pyruvate kinase in cells is to catalyse the last step of glycolysis. The 
last step which is the rate limiting step involves, Trans-phosphorylation of PEP 
(phophophenolpyruvate) to ADP. Also, this step gives the net energy generation in glycolysis. 
In humans, M1 and M2 isomers are encoded in PKM gene, each of which are alternate splicing 
products (Gupta and Bamezai, 2011). From different isomeric forms of pyruvate kinase, L-
form is expressed where there is high requirement of glucogenesis whereas, the M-form is 
expressed in in muscle and brain cells where there is high requirement of energy (Tsutsumi et 
al., 1988). 
                         
               Figure 3. Structure of tumor-PKM2. 
 
2.1.3. Functioning of PKM2 in cellular pathways: 
Form Warburg’s theory, dividing cells depend upon glycolysis for ATP as well as 
intermediates. Both of these being mutually exclusive the reaction is carried out in a cyclic 
manner where PKM2 being prevalent at the last step of glycolysis has a major role (Gupta and 
Bamezai, 2011). The presence of PKM2 isomer in proliferating cells channels the metabolites 
from glycolytic pathway into nucleogenic pathway. Whenever there is a need for intermediates 
for macromolecule generation the tetramer PKM2 dissociates into dimer form of PKM2. As a 
result there is accumulation of glycolytic intermediates and hence, they are channelled into 
other pathways such as Pentose Phosphate Pathway (Gupta and Bamezai, 2011). There is a 
state of equilibrium between PKM2 dimer and tetramer as in cancer cells there is a continuous 
need of glycolytic metabolites. Other roles of PKM2 in tumorigenesis include – 
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1. PKM2 possess a positive feedback regulation towards HIF-1.  
2. PKM2 up-regulates c-MYC transcription and hence plays an important role in c-MYC-
mediated cancer metabolism (Wong et al., 2013). 
Tumor cells express high levels of PKM2 dimer. From the four forms of PK isoforms, only 
PKM2 dimer and tetramer are allosterically regulated (10). Tyrosine phosphorylated peptides 
when bind to PKM2 there is dissociation of FBP and hence, dimer is formed. Dissociation of 
FBP leads to dimerization of PKM2 which promotes Warburg effect i.e. lactate formation.  
 
          
 
         Figure 4. PKM2 as a metabolic sensor in Glycolytic pathway. 
 
Rather than being organ specific tumor-PKM2 is highly expressed in many types of tumors 
such as gastro-intestinal cancer, breast cancer, colon cancer etc. Being a key enzyme in cancer 
cell metabolism this isoform is found in high concentrations in malignant tissues, body fluids 
and blood plasma. There is difference between the affinity of the two forms of PKM to their 
substrate i.e. glucose metabolite phosphophenol pyruvate, which is an energy storing 
metabolite (Mazurek et al., 1997). There is a hypothesis that, due to the predominance of dimer 
PKM2 in cancer cells, in these cells the pyruvate consumption of mitochondria is very low 
hence low dependence of tumor cell upon gluconeogenesis (Eigenbrodt et al., 1992). Majorly, 
tumor pyruvate kinase M2 isomer is found in colon cancer cells and esophagal cancer cells 
(Mazurek et al., 2000). Recently, effort is being diverted to concentrate upon targeting tumor-
10 
 
PKM2 and to find non-toxic inhibitors for the same so as to target cancer metabolism (Mazurek 
et al., 2000).  
 
2.2 Inhibitors specific to tumor-PKM2: 
                         
Different small molecule inhibitors with high affinity have been used to target pyruvate kinase 
in different organisms to study the functioning of pyruvate kinase which has a central role in 
cellular metabolism (Morgan et al., 2012). 
  
2.2.1 DBS- {4-((1, 1-dioxo-1, 2-benzothiazol-3-yl) sulfanyl) benzoic acid}:   
Through high throughput screening it was seen that derivatives of saccharin inhibit PKL in an 
irreversible manner. When DBS was bounded to PKL it was seen that, it reacted with lysine 
residue and hence, preventing the binding of ADP/ATP. All other isoenzymes of PKY in 
humans were found to be irreversibly inhibited by dibenzylidene sorbitol (Morgan et al., 2012).  
Other similar structure ligands or inhibitors used have been shown in Table 1. 
 
Table 1. Structure of DBS and its analogues. 
 
 
 
Molecule 
 
Structure 
 
 
 
 
Diacetyl dibromosalicyl 
         
11 
 
 
 
 
 
 
Dabsyl-L-proline 
                 
 
 
 
 
 
Dbs-Trp-OH 
 
 
 
 
 
Dbs-Val-OH 
                  
 
 
 
2.2.2 Shikonin : 
A class of necroptotic inducers that have been known to bypass resistance of cancer drugs. It 
has been shown that shikonin and alkanin can selectively inhibit pyruvate kinase M2 over 
PKM1 and PKL up-to above 50% inhibition. The results showed that they inhibited glycolytic 
metabolism to a significant rate (Chen et al., 2011). Till now they are known to be the most 
specific and potent inhibitors for pyruvate kinase M2. 
The structure of shikonin and its analogues have been shown below – 
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Table 2. Structure of Shikonin and its analogues. 
 
 
Molecule Structure 
 
 
Shikonin 
 
 
 
Acetylshikonin 
 
 
 
Shikonin beta 
 
 
 
 
Shikonin Leucoacetate 
 
 
 
Shikonin Propionate 
 
 
 
 
Shikonin Angelate 
 
 
 
2.2.3 FASN inhibitors: 
 
Under therapeutic strategies to inhibit cancer cell metabolism, targeting the upstream regulators 
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of the cellular pathways has been one of the most expected one. Several regulators such as HIF 
(hypoxia inducible factor), PI3K, mTOR, pyruvate kinase, AMP activated protein kinase etc. 
can be targeted. FASN is a multi-functional protein. In the past several FASN inhibitor have 
been used with positive results for inhibition of fatty acid synthase. In case of metastatic 
melanoma and renal carcinoma TLN-232 has been used to target pyruvate kinase to inhibit 
glycolysis (Tennant, Duran and Gottlieb, 2000). 
Other FASN inhibitors that can be used are- 
 
Table 3. Structure of Cerulenin and its analogues. 
 
 
Molecule Structure 
 
 
 
Cerulenin 
 
 
 
AC1L6R79 
 
 
 
 
Helicocerin 
 
 
 
NSC116069 
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Table 4. Structure of Kaempferol and its analogues. 
 
 
Molecules Structures 
 
 
 
Kempferol 
 
 
 
 
 
Sophoraflavonoloside 
 
 
 
 
Kaempferol-3-rutinoside 
 
 
 
 
Kaempferitrin 
 
 
 
 
Kaempferol 7-O-glucoside 
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Table 5. Structure of Quercetin and its analogues. 
 
 
Molecule Structure 
 
 
 
Quercetine 
 
 
 
 
Quercetin 3-O-glucuronide 
 
 
 
 
Quercetin 3-rhamnoside 
 
 
 
 
Isoquercetin 
 
 
 
 
 
Hyperoside 
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 Table 6. Structures of Triclosan and its analogues. 
 
 
Molecules Structures 
 
 
 
Triclosan 
 
 
 
 
 
Methyl Triclosan 
 
 
 
 
 
Triclosan-d3 
 
 
 
 
Triclosan Methyl-d3 Ether 
 
 
 
2.2.4 SOD (Superoxide Dismutases): 
 
For the survival of cancer cells there should be a control to the intracellular ROS (Reactive 
Oxygen Species). It has been shown in lung cancer cells of humans when ROS concentration 
is increased, pyruvate kinase is inhibited due to oxidation of cysteine 358 (Anastasiou et al., 
2011). But here, there is a disadvantage as there is risk of cellular damage at high concentrations 
of reactive oxygen species (Wellen and Thompson, 2010). Oxidants have been known to inhibit 
Pyruvate Kinase in many organisms (Maeba and Sanwal, 1968; McDonah et al., 2009; 
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Butterfield and Sultana, 2007; Cumming et al., 2004). A549 (lung cancer cell line) when 
exposed to hydrogen peroxide and diamide, resulted in inhibition of pyruvate kinase activity 
(Brunelle et al., 2005). 
 
Other reactive oxygen species which can be used are shown in the table below- 
 
Table 7. Structure of SOD and its analogues. 
 
Molecule Sturcture 
 
 
 
Zalcitabine 
 
 
 
 
Zidovudine 
 
 
 
 
Didanosine 
 
 
 
 
 
SOD 
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3.1 Tools and Softwares: 
 
      Computational biology and Bioinformatics have the potential to speed up drug discovery 
processes, reducing the costs of the processes and changing the way the drugs are designed. 
Rational drug design facilitates and speeds up the drug designing processes that involves 
various method of identifying novel compounds. One advanced method is the docking of the 
drug molecule or ligand or inhibitor with the target. The site where the drug binds is known to 
the site of action, which is responsible for the pharmaceutical effect is the target. Docking is 
the method by which two molecules bind to each other in 3D space. There are various tools, 
software and servers meant for docking calculations.  
 
3.1.1 Softwares used are: 
 Swiss-PdbViewer 
 Argus Lab 4.0.1 
 Auto Dock 4.0 
 Auto DockVina 1.0 
 Chimera 1.9  
 MGL Tools 1.5.6 
 Open Babel GUI 
 EasyConvert  
 
3.1.2 Online servers which were used are: 
 http://www.rcsb.org/ 
 https://pubchem.ncbi.nlm.nih.gov/ 
 http://www.swissdock.ch/ 
 http://projects.biotec.tu-dresden.de/metapocket/ 
 http://sts-fw.bioengr.uic.edu/castp/calculation.php 
 http://uniprot.org 
 
3.1.3 Files Required for docking: 
 PDB file of targeted protein(PKM2). 
 SDF files of tumor-PKM2 Inhibitors. 
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 PDB files of PKM2 Inhibitors using Open Babel. 
 PDBQT files of both targeted protein(PKM2) and Its Inhibitors. 
 
3.2 Procedure followed: 
 
        In this in-silco based screening, protein PKM2 (PDBID-3SRH) has been selected which 
plays a critical role in the glycolytic pathway in several cancer cells. This protein is responsible 
for most of the energy generation in cancer cells as well as diversion of glycolytic metabolites 
into other pathways for synthesis of macromolecules. These macromolecules help in cell 
growth and proliferation. 
 
3.2.1 Inhibition of PKM2: 
 
Retrieval of 3D structure PKM2 protein from rcsb.org PDB (3SRH). 
 
 
Collect SDF files of PKM2 Inhibitors molecule from PubChem database. 
 
 
Modification of ligand molecules was by Chemsketch and Chemspider 
   
 
Energy minimization of inhibitor ligands using ProDrg sever 
 
 
Conversion of SDF files into PDB files using Open Babel software 
 
 
PDB files of Both Protein (PKM2) and Ligand inhibitors are converted into PDBQT file 
Using Auto Dock 4.0  
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Docking of all PKM2 inhibitors with PKM2 molecule is done using AutoDockVina 
 
 
Analysing the binding energy results obtained from the molecular docking 
 
 
Calculating the Toxicity of individual inhibitor molecules for priority purpose 
 
 
3.3 Methodology: 
 
        Molecular docking is a method which is used for the prediction of preferred orientation 
of one molecule to other molecule when bound form a stable. It is frequently used to predict 
the binding energy of small molecular drugs to the targeted protein in order to predict affinity 
and activity. 
 
3.3.1 Retrieval of amino acid sequences of PKM2 protein from NCBI: 
 
          NCBI stands for National Centre for Biotechnological Information. It is established as 
a division of National Library of Medicines at National Institutes of Health. The NCBI 
responsible for creating automated systems of knowledge about molecular biology, 
biochemistry, and genetics, providing the use of such databases and software by the research 
and medical community; collect biotechnology information both nationally and internationally; 
and execution research on advanced methods of computer-based information processing for 
examining the structure and function of biologically important molecules. The URL for this 
database is http://www.ncbi.nlm.nih.gov. 
 The above mentioned URL was browsed. 
 In search option, protein was mentioned and Pyruvate kinase human was 
typed. 
 There were many results of the search but the accession number AAA60104.1 
was selected and the sequences were retrieved in Fasta format 
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      Figure 5. FASTA format of PKM2. 
3.3.2 Retrieval of 3D structure of PKM2 Protein modelled by PHYRE2: 
PHYRE is an automatic fold recognition server for calculating the structure and function of the 
protein sequence that got submitted in the server. It is used for academic users only. It uses the 
principle and technique of Homology Modelling and relies on Hidden Markov Models. 
 The Fasta format of amino acid sequences was pasted and Phyre 2 search was 
clicked. 
 After some time the results were sent to the user given email address. 
 The modelled structure was retrieved from the link sent by the server. 
 
 
3.3.3 Energy minimization of all 3D structure of proteins by Chimera 1.7: 
UCSF CHIMERA 1.7 is an extensible programme for visualization and analysis of molecular 
structure and related data including density maps, supramolecular associations, sequence 
alignments, docking results, routes and conformational ensembles. One of the best features is 
the structural editing job. It can minimize the energy of molecules providing them high 
stability. 
 Chimera window was opened. 
 From the option file, the 3D structure of protein was retrieved. 
 The total residues were selected. 
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 From the tool option, by the structure editing option, minimized structure option 
was clicked.  
 The minimized structure was saved in .pdb format. 
3.3.4 Geometry Optimization of all 3D structure of proteins by ArgusLab:  
           Argus Lab is one of the important software which is used for the geometry optimization 
of the Protein molecule which we need to dock. This is done because when we dock with the 
ligand molecules it gives a perfect result without any errors. It optimize the geometry of the 
molecule for better orientation. 
 ArgusLab 4.0 window was opened. 
 From the option file, the 3D structure of protein was retrieved. 
 Then go to geometry optimization tools. 
 From the tool option, by the structure editing option, Optimize geometry option was 
clicked.  
 The Optimized structure was saved in .pdb format. 
          
          Figure 6. PKM2 in ArgusLab. 
 
 
3.3.5 Collect SDF files of PKM2 Inhibitors molecule from PubChem: 
         PubChem is a database of chemical structures of small organic molecules and contain 
information of their biological activity, origin and related literatures. It is executed and updated 
by NCBI and is freely available. Millions of compound structures and data seta can be freely 
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downloaded in .sdf format or chemical (CID) format. 
 PubChem page was retrieved by browsing Pubchem.ncbi.nlm.nih.gov. 
 In search bar individual inhibitors name was typed and entered. 
 All the available ligands of therapeutic target database retrieved in .sdf file 
format. 
 The ligands retrieved were Cerulenin, DBS, kaempferol, l-phospholactate, 
Quercetin, Shikonin, SOD, Triclosan etc. 
 
Figure 7. Structure of Shikonin in PubChem. 
 
 
3.3.6 Conversion of .sdf file format to .pdb by Open Babel GUI: 
         Open Babel 2.3.1 is a chemical toolkit designed to interpret the various language of 
chemical data. It allows searching, converting, and analysing chemical data. It supports 
Cheminformatics, molecular modelling, and bioinformatics. It covert chemical datafrom one 
file format to another. 
 Open Babel 2.3.1 window was opened. 
 The input format was selected as .sd and the output format as .pdb. 
 From the input option .sd file was browsed. 
 Click on the convert option to convert .sd file format to .pdb file format. 
 Then the selected files were generated in the .pdb file format and saved. 
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       Figure 8. Conversion from .sdf to .pdb in open babel. 
 
3.3.7 Conversion of .pdb to .pdbqt of Molecules Using Auto Dock 4.0: 
         Auto Dock 4.0 is an Interactive Molecular graphics program developed by The Scripps 
Research Institute for estimating docking calculations and displaying docking modes of pairs 
of protein and ligand molecules. Auto Dock is used as the docking tool which calculates 
intermolecular “energies” by adding up all intermolecular interactions, adding polar hydrogens 
and also the kollmann charges to the protein molecule (e.g. van der Waals, electrostatic) that 
occur between a ligand and protein target. 
 
 Auto Dock 4.0 window was opened. 
 
3.3.7.1 Covert .pdb of PKM2 molecule to .pdbqt: 
 1.File       Read molecule 
(This will open a file browser, showing all the files in the current directory. 
Select target.pdb and click on Open) 
 2. Edit        Hydrogens       Add Polar only 
 3. Edit        charges       Add kollmann charges 
 5. File       Save        write .pdbqt 
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3.3.7.2 Covert .pdb of Inhibitor molecule to .pdbqt: 
1.  Ligand       Input Molecule         Read Molecule 
(Opens a file browser. Click on the PDB files: (*.pdb) menu button to display file 
type choices and click on PDB files: (* .pdb) files. Choose ind.pdb. Click on Open.) 
2. Ligand       torsion tree       choose root 
3. Ligand        torsion tree       detect root 
4. Ligand        output       save as .pdbqt. 
 
3.3.7.3 Grid setting for the location of ligand to be Dock: 
 
1. Grid        Macromolecule         Choose Macromolecule 
Choose target 
2. Grid        Set Map Types          Choose Ligand       select Ligand 
3. Grid         Grid Box 
a. Opens the Grid Options Widget 
b. Adjust the number of points in each dimension to 20. 
c. The spacing between grid points can be adjusted & the default value is 1.000 Å 
between grid points. 
d. Type in 24.891, -19.303 and 11.573 (Alanine) in the x center, y center and z 
center entries. This will center the grid box on the active site. 
e. Close this widget by clicking File        Close saving current. 
4. Grid        output        save as .pdbqt 
 
3.3.8 Molecular Docking Using Auto DockVina: 
 
         AutoDock Vina significantly improves the average accuracy of the binding mode 
predictions compared to AutoDock 4, judging by various tests according to The Scripps 
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Research Institute the training set used in AutoDock 4 development. Additionally and 
independently, AutoDock Vina has been tested against a virtual screening benchmark called 
the Directory of Useful Decoys. 
 Open the Command prompt in the system. 
 Give the location where the .pdbqt files of both Protein and inhibitor in cmd. 
 Then give the location of program vina in the program file for processing 
                         
 
Figure 9. AutoDock vina in cmd. 
 
 Create a conf.txt file giving the information of configuration for the Docking process. 
                  
Figure 10. Conf file of Sophoraflavonoloside. 
 
 Give the command in the cmd for docking procedure to initiate. 
 Result is displayed in the log file generated by the AutoDock Vina.  
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Figure 11. Log file of Quercetin. 
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4.1 Selection of Target pathway: 
 
      Out of all the pathways that play an important role in cancer cell growth and proliferation, 
Glycolytic pathway was selected to be the target pathway. This pathway controls the major part 
of energy generation in cancer cells and also, it provides macromolecules required for the 
synthesis of bio-molecules that are necessary for the growth and proliferation of cancer cells. 
  
4.2 Interaction between PKM2 and small molecule inhibitors: 
 
    After retrival of structure of tumor-PKM2, and generating pdbqt files of both target 
molecule (tumor-PKM2) and small molecule inhibitors, docking was carried out using 
Autodock Vina. Docking results of PKM2 with different inhibitors were studied and the best 
result was noted. After noting the best results the toxicity of different inhibitors used was 
checked. 
 
4.1.1 Docking with Cerulenin and similar molecules: 
           All selected ligands or inhibitors were docked with PKM2, at different binding sites, to 
find their BINDING ENERGY. The results are shown in the table below- 
 
Table 8. Docking of Cerulenin and its analogues with PKM2. 
 
LIGAND BINDING SITES BINDING ENERGY 
(kcal/mol) 
 
Cerulenin 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.5 
-6.2 
-7.1 
-6.3 
 
AC1L6R79 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.5 
-7.2 
-4.6 
-4.5 
 
Helicocerin 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.6 
-6.5 
-7.1 
-6.6 
 
NSC116069 
73 (Alanine) 
482 (Methionine) 
-6.5 
-6.5 
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 295 (Asparagine) 
464 (Glutamic acid) 
-6.5 
-6.4 
 
The best result was found with Cerulenin at binding site 295 (Asparagine) and Helicocerin at 
binding site 295 (Asparagine). Hence, it was concluded that these two molecules are capable 
enough to inhibit the target protein. 
 
4.1.2 Docking with DBS and other similar molecules: 
           DBS which reacts with binding site having Lysine residue, forms covalent bonding and 
thus hindering the binding of ATP at the site. There is irreversible binding at the site. After 
docking in Auto Dock Vina the following results were found- 
 
Table 9. Docking of DBS and its analogues with PKM2. 
 
LIGAND BINDING SITES BINDING ENERGY 
(kcal/mol) 
 
Diacetyl Dbs 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-5.6 
-6.3 
-6.2 
-5.6 
 
AG-H-60909 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-8.1 
-7.5 
-6.1 
-5.5 
 
Dbs-Trp-OH 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-8.1 
-7.6 
-1.2 
-6.1 
 
Dbs-Val-OH 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-7.3 
-7.1 
-4.2 
-6.1 
 
The best result was found with AG-H-60909 and Dbs-Trp-OH at binding sites 73 (Alanine). 
Thus these small molecule inhibitors have high binding efficiency at -8.1 kcal/mol. 
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4.1.3 Docking with Kaempferol and other similar molecules: 
           Upon docking of Kaempferol and other similar small molecule inhibitors with PKM2 at 
the different binding sites the following result was found and listed as below- 
 
Table 10. Docking of Kaempferol and its analogues with PKM2. 
 
LIGAND BINDING SITES BINDING ENERGY 
(kcal/mol) 
 
Kempferol 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-7.7 
-7.1 
-7.3 
-6.5 
 
Sophoraflavonoloside 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.2 
-7.6 
-7.3 
-7.8 
 
Kaempferol-3-rutinoside 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.4 
-6.3 
-6.3 
-6.8 
 
Kaempferitrin 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-4.1 
-5.4 
-5.8 
-5.7 
 
Kaempferol 7-O-glucoside 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.1 
-6.1 
-5.8 
-5.9 
 
The best result was found with Kaempferol at -7.7 kcal/mol, concluding that this molecule can 
act as highly efficient inhibitor for the target protein and hence, can act as a drug to inhibit the 
glycolytic metabolism in cancer cells. Doing so, it can prevent channelling of macromolecules 
into other pathways, and thus hindering cell proliferation. 
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4.1.4 Docking with L-phospholactate and other similar molecules: 
 
Table 11. Docking of L-Phospholactate and its analogues with PKM2. 
 
LIGAND BINDING SITES BINDING ENERGY 
(kcal/mol) 
 
L-Phospholactate 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-4.9 
-4.8 
-5.1 
-5.5 
 
S-phospholactate 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-4.9 
-4.6 
-1.2 
-6.1 
 
2-phospho-L-lactate dianion 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-4.8 
-4.4 
-4.2 
-5.1 
 
 
4.1.5 Docking with Quercetin and other similar molecules: 
Upon docking of Kaempferol and other similar small molecule inhibitors with PKM2 at the 
different binding sites the following result was found and listed as below- 
 
Table 12. Docking of Quercetin and its analogues with PKM2. 
 
LIGAND BINDING SITES BINDING ENERGY 
(kcal/mol) 
 
Quercetin 3-O-glucuronide 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.8 
-6.7 
-6.9 
-6.3 
 
Quercetine 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-8.0 
-8.1 
-8.2 
-6.6 
 
Quercetin 3-rhamnoside 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.9 
-7.4 
-7.3 
-6.1 
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Hyperoside 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.8 
-6.9 
-6.4 
-6.4 
 
The best result was found with CID5280343 at -8.0 kcal/mol, at different binding sites, 
concluding that this molecule can act as highly efficient inhibitor for the target protein and 
hence, can act as a drug to inhibit the glycolytic metabolism in cancer cells. Doing so, it can 
prevent channelling of macromolecules into other pathways, and thus hindering cell 
proliferation. 
 
4.1.6 Docking with Soc3 and other similar molecules: 
 
Table 13. Docking of Soc3 and its analogues with PKM2. 
 
LIGAND BINDING SITES BINDING ENERGY 
(kcal/mol) 
 
SOC 3 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.1 
-6.3 
-6.0 
-7.1 
 
This ligand, Soc3 gave low binding efficiency and thus there is no point of using this inhibitor 
to stop the action of PKM2. 
 
4.1.7 Docking with Shikonin and other similar molecules: 
 
Table 14. Docking of Shikonin and its analogues with PKM2. 
 
LIGAND BINDING SITES BINDING ENERGY 
(kcal/mol) 
 
Shikonin 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-7.5 
-6.9 
-6.8 
-5.9 
 
Glutamic acid 
73 (Alanine) 
482 (Methionine) 
-6.8 
-6.5 
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 295 (Asparagine) 
464 (Glutamic acid) 
-6.4 
-5.9 
 
Shikonin beta 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-7.9 
-7.5 
-7.1 
-6.1 
 
Shikonin Leucoacetate 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-5.1 
-5.7 
-5.9 
-6.0 
 
Shikonin 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.3 
-6.0 
-6.8 
-6.3 
 
Alanine 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.8 
-6.1 
-6.2 
-4.1 
 
Shikonin angelate 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.2 
-4.9 
-5.0 
-6.2 
 
The docking of ligands was carefully observed and their interaction and orientations were also 
monitored.  
Results showed that Shikonin has highest binding affinity of -7.9 Kcal/mol, at binding site 73 
(Alanine). Hence these ligands having high affinity than ATP can be used as tumor-PKM2 
inhibitor. The ligand being more competent than ATP molecule, might replace ATP when it 
enters cytoplasm and might bind to the active site of PKM2 which will further interrupt its role 
in glycolytic metabolism. 
 
 
4.1.8 Docking with Triclosan and other similar molecules: 
All selected ligands or inhibitors were docked with PKM2, at different binding sites, to find 
their BINDING ENERGY. The results are shown in the table below- 
 
Table 15. Docking of Triclosan and its analogues with PKM2. 
 
LIGAND BINDING SITES BINDING ENERGY 
(kcal/mol) 
 73 (Alanine) -7.3 
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Triclosan 
 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.7 
-6.8 
-4.9 
 
Methyl Triclosan 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.8 
-1.7 
-5.5 
-6.1 
 
Triclosan-d3 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-7.3 
-6.6 
-6.8 
-4.9 
 
Triclosan Methyl-d3 Ether 
 
73 (Alanine) 
482 (Methionine) 
295 (Asparagine) 
464 (Glutamic acid) 
-6.8 
-6.1 
-6.2 
-6.5 
 
Triclosan and its analogues show average binding efficiency at different binding sites of tumor-
PKM2 protein. Though triclosan at binding site 73 (Alanine) shows a high binding efficiency 
of -7.3 Kcal/mol and apparently can be used as an inhibitor for tumor-PKM2. This ligand can 
further be experimented and varied with some functional groups to give better results.  
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5.1 CONCLUSION: 
 
Since the last century, the disease cancer has been a central focus of research in the field of 
biotechnology and medicines. Till present there has been no effective drug against cancer. Thus 
there is a need to find and create drugs that can target the hallmark metabolic pathway of cancer 
cells and hence lead to their death. Since 1972, when the tumor protein pyruvate kinase was 
discovered it has been seen as the primary target for glycolytic metabolism inhibition. 
Targeting Pyruvate Kinase M2, which is expressed in most cancer cells can be a promising 
method of cancer inhibition.  
Here, tumor-PKM2 has been targeted by small molecule inhibitors such as Shikonin, 
Cerulenin, Soc3, Quercetin, DBS, L-Phospholactate, Kaempferol and their several analogues. 
Cerulenin, Helicocerin, AG-H-60909, Dbs-Trp-OH, Quercetin showed high binding efficiency 
of 7.1, 7.1, 8.1 and 8.2 Kcal/mol respectively.  
The best result was found to be Quercetin at Asparagine binding site. The binding energy at 
this site was found to be 8.2 Kcal/mol. This molecule with a cancer cell selective marker may 
be used a drug for targeting glycolytic metabolism which will highly affect cancer cell 
proliferation and arrest its major energy source.  
However, there can be other more efficient inhibitors which might show a better activity. Thus, 
there is a need for more intense research in this field and also, search for proper non-toxic 
cancer cell specific markers has to be done. 
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